[Current developments in surgery and radiotherapy for the treatment of seminoma stage IIA/B].

IF 0.4 4区医学 Q4 UROLOGY & NEPHROLOGY

Urologie Pub Date : 2025-10-01 Epub Date: 2025-09-02 DOI:10.1007/s00120-025-02672-9

Yue Che, Alexandros Papachristofilou

{"title":"[Current developments in surgery and radiotherapy for the treatment of seminoma stage IIA/B].","authors":"Yue Che, Alexandros Papachristofilou","doi":"10.1007/s00120-025-02672-9","DOIUrl":null,"url":null,"abstract":"Background: Stage IIA/B seminoma is cured in over 90% of cases with standard therapies (polychemotherapy, large-volume radiotherapy). However, these treatments are associated with potential late toxicities.Materials and methods: This article addresses current developments from a urological-surgical and radiotherapeutic perspective in the treatment of stage IIA/B seminoma. Current study results are presented, and possible developments are outlined.Results and conclusion: Retroperitoneal lymphadenectomy (RLA) has the potential to offer a radiation- and chemotherapy-free treatment alternative. It was investigated in the recently published PRIMETEST, SEMS, and COTRIMS studies. Current clinical research focuses on the choice of template (unilateral vs. bilateral), the surgical approach (open vs. robotic), and the potential use of adjuvant chemotherapy after RLA (ongoing PRIMETEST II study). A combined, de-escalated chemoradiotherapy was evaluated in the SAKK 01/10 study and yielded very good results regarding recurrence-free survival and toxicity. Long-term results are still awaited, as are the results of the study SAKK 01/18.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"1018-1023"},"PeriodicalIF":0.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02672-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/2 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Stage IIA/B seminoma is cured in over 90% of cases with standard therapies (polychemotherapy, large-volume radiotherapy). However, these treatments are associated with potential late toxicities.

Materials and methods: This article addresses current developments from a urological-surgical and radiotherapeutic perspective in the treatment of stage IIA/B seminoma. Current study results are presented, and possible developments are outlined.

Results and conclusion: Retroperitoneal lymphadenectomy (RLA) has the potential to offer a radiation- and chemotherapy-free treatment alternative. It was investigated in the recently published PRIMETEST, SEMS, and COTRIMS studies. Current clinical research focuses on the choice of template (unilateral vs. bilateral), the surgical approach (open vs. robotic), and the potential use of adjuvant chemotherapy after RLA (ongoing PRIMETEST II study). A combined, de-escalated chemoradiotherapy was evaluated in the SAKK 01/10 study and yielded very good results regarding recurrence-free survival and toxicity. Long-term results are still awaited, as are the results of the study SAKK 01/18.

查看原文本刊更多论文

[精原细胞瘤IIA/B期手术和放疗的最新进展]。

背景：IIA/B期精原细胞瘤采用标准治疗（多化疗、大容量放疗）治愈率超过90%。然而，这些治疗与潜在的晚期毒性有关。材料和方法：本文从泌尿外科和放射治疗的角度阐述了目前治疗IIA/B期精原细胞瘤的进展。介绍了目前的研究结果，并概述了可能的发展。结果和结论：腹膜后淋巴结切除术（RLA）有可能提供一种无放疗和无化疗的治疗选择。最近发表的PRIMETEST， SEMS和COTRIMS研究对其进行了调查。目前的临床研究主要集中在模板的选择（单侧还是双侧）、手术入路（开放还是机器人）以及RLA后辅助化疗的潜在使用（正在进行的PRIMETEST II研究）。SAKK 01/10研究评估了一种联合的、降级的放化疗，在无复发生存和毒性方面取得了非常好的结果。长期结果仍在等待，SAKK 01/18研究的结果也是如此。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologie UROLOGY & NEPHROLOGY-

CiteScore

1.00

自引率

0.00%

发文量